Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience

Cabozantinib is an oral multitargeted tyrosine kinase inhibitor (TKI) that potently inhibits MET and AXL, both associated with poor prognosis in renal cell carcinoma (RCC), next to vascular endothelial growth factor receptor 2, KIT, FLT3 and RET. Chronic treatment with vascular endothelial growth fa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ther Adv Urol
Hauptverfasser: Osanto, Susanne, van der Hulle, Tom
Format: Artigo
Sprache:Inglês
Veröffentlicht: SAGE Publications 2018
Schlagworte:
Review
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5896860/
https://ncbi.nlm.nih.gov/pubmed/29662541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287217748867
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge